Log in to save to my catalogue

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK i...

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04633807v1

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Publication information

Publisher

New York: Springer New York

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Genomic and drug screens identify SHP2 blockade as a therapeutic approach for ALK-rearranged non-small cell lung cancers developing resistance through ALK-mutant-independent mechanisms.
Most anaplastic lymphoma kinase (
ALK
)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often...

Alternative Titles

Full title

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_04633807v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04633807v1

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X,1744-7933

DOI

10.1038/nm.4497

How to access this item